Last reviewed · How we verify
Dexmedetomidine 0.6
At a glance
| Generic name | Dexmedetomidine 0.6 |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Opioid-Free vs Opioid-Based Anesthesia for Nasal Surgeries (PHASE3)
- Effect of Dexmedetomidine on Tear Production in Angioplasty Patients (NA)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Effectiveness of Dexmedetomidine Versus Sufentanil on Cerebral Oxygen Saturation in Patients With Traumatic Brain Injury (NA)
- Perioperative Pain Management for Lumbar Spine Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine 0.6 CI brief — competitive landscape report
- Dexmedetomidine 0.6 updates RSS · CI watch RSS
- Tanta University portfolio CI